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Abstract
We present the treatment rationale and study design of the AvaALL (MO22097; ClinicalTrials: NCT01351415) trial, a multicenter,
open-label, randomized, two-arm, phase IIIb study. Patients with advanced non-squamous non–small-cell lung cancer (NSCLC)
whose disease has progressed after four to six cycles of first-line treatment with bevacizumab plus a platinum-based doublet
and a minimum of two cycles of bevacizumab (monotherapy) maintenance treatment will be randomized in a 1:1 ratio to one of
two study arms. Patients treated on arm A will receive bevacizumab 7.5 or 15 mg/kg intravenously (I.V.) on day 1, every 21 days
plus, investigator’s choice of agents indicated for use in second-line (limited to pemetrexed, docetaxel, or erlotinib) and
subsequent lines of treatment. Patients treated on arm B, will receive investigator’s choice of agents alone indicated for use in
second-line and subsequent lines of treatment, but no further bevacizumab treatment. The primary endpoint of this study is
overall survival (OS). Secondary endpoints include the 6-month, 12-month, and 18-month OS rates, progression-free survival,
and time to progression at second and third progressive disease (PD), response rate, disease control rates, and duration of
response at second and third PD. Additionally, efficacy in the subgroup of patients with adenocarcinoma, and the safety of
bevacizumab treatment across multiple lines of treatment will be assessed. Exploratory objectives include assessment of the
quality of life through multiple lines of treatment, comparison of the efficacy between Asian and non-Asian patients, and
correlation of biomarkers with efficacy outcomes, disease response, and adverse events.
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408Introduction
Angiogenesis, whether physiological or pathological, is governed
by a host of proangiogenic and antiangiogenic factors. Solid tumors
secrete proangiogenic factors, among which vascular endothelial
growth factor (VEGF) is the most potent and specific of the endo-
thelial cell mitogens that stimulate angiogenesis and, consequently,
tumor development and metastatic activity. VEGF is both present
and stable throughout the tumor life cycle.1-5 VEGF and its recep-
ors have been a major focus of basic research and drug development
n the field of oncology.6,7 Approaches targeting VEGF include
monoclonal antibodies and small molecule VEGF receptor-tyrosine
kinase inhibitors (VEGFR-TKIs).8 The inhibition of VEGF signal-
ng through its specific inhibitors, both in in vitro and in vivo exper-
ments, showed vessel regression and normalization as well as stromal
aturation, resulting in a reversion to a noninvasive tumor pheno-
ype. Preclinical evidence supports maintaining direct and continu-
us VEGF suppression over time. As tumors develop, continued
EGF suppression may provide important ongoing antivascular ef-
ects that may inhibit further growth and spread of tumor cells.
hen the inhibitor agent is suspended, new vessel growth starts,
hereby favoring tumor development and metastatic dissemination
gain.9,10 However, preclinical evidence does not support the induc-
ion of a more aggressive tumor phenotype after cessation of bevaci-
umab.11 Additionally, a pooled analysis of more than 4000 patients
cross four tumor types neither supports accelerated tumor growth,
or the development of a more aggressive tumor phenotype.12
The majority of patients diagnosed with non–small-cell lung can-
cer (NSCLC), have advanced disease at diagnosis. Chemotherapy is
the mainstay for palliative management of symptoms and survival
improvement in these patients. Standard of care for the first-line
therapy of advanced NSCLC is a platinum-based doublet. However,
until very recently, no doublet combination has been proven to be
clinically superior to any other in the treatment of advanced NSCLC,
despite the availability of new combinations of cytotoxic agents.13-15
The only exception is the phase III trial conducted by Scagliotti et
al,16 a noninferiority trial, which demonstrated modest survival im-
rovements for cisplatin-pemetrexed compared to cisplatin-gemcit-
bine in patients with advanced NSCLC with non-squamous histol-
gy. Conversely, cisplatin-pemetrexed demonstrated inferior efficacy
ompared to cisplatin-gemcitabine in patients with squamous histol-
gy. Furthermore, there are only limited treatment options for those
atients whose disease progresses during first-line chemotherapy.
urrently, docetaxel and pemetrexed, two widely used chemother-
py agents, and erlotinib, an epidermal growth factor receptor
EGFR) TKI, are the only agents registered for use in patients with
SCLC who do not benefit from upfront chemotherapy.13-15
Bevacizumab, a humanized monoclonal antibody directed against
VEGF, is currently the first and only pure antiangiogenic agent ap-
proved for the treatment of various cancers, including NSCLC.17
Based on the promising data of a phase II randomized trial,18 two
randomized phase III trials were conducted to compare a regimen of
chemotherapy alone versus chemotherapy plus bevacizumab in the
first-line treatment of advanced non-squamous NSCLC.19-21 Squa-
mous histology was excluded in subsequent trials because of the sig-
nificant risk of grade 5 hemoptysis reported in the phase II study.18In the first phase III randomized trial (Eastern Cooperative Oncol-
Clinical Lung Cancer November 2011ogy Group [ECOG] E4599), 878 enrolled patients with non-squa-
mous NSCLC received either carboplatin plus paclitaxel alone or in
combination with bevacizumab (15 mg/kg, intravenously [I.V.] ev-
ery 21 days). Statistically significant advantages in overall survival
(OS; median 12.3 vs. 10.3 months; hazard ratio [HR], 0.79; P 
0.003), progression-free survival (PFS; median 6.2 vs. 4.5 months;
HR 0.66; P 0.001) and response rate (35% vs. 15%; P 0.001)
ere reported in favor of the combination of chemotherapy plus
evacizumab.19 Furthermore, in a preplanned retrospective analysis
f patients with adenocarcinoma, bevacizumab-based treatment im-
roved median OS to 14.2 months (HR, 0.69).20 In the Avastin in
Lung (AVAiL) trial, 1043 patients with non-squamous NSCLC were
enrolled and randomized to three arms: cisplatin plus gemcitabine in
combination with placebo, or two different doses of bevacizumab
(7.5 or 15 mg/kg, I.V., every 21 days).21,22 PFS, the primary end-
oint of the trial, was significantly prolonged with the addition of
evacizumab to chemotherapy, compared with placebo; the HRs
ere 0.75 (P 0.003; median PFS 6.7 vs. 6.1 months for placebo)
in the 7.5 mg/kg group and 0.82 (P 0.03; median PFS 6.5 vs. 6.1
onths for placebo) in the 15 mg/kg group, respectively. No OS
dvantage for the bevacizumab-containing arms was observed.
The tolerable and manageable safety profile observed in the above
entioned trials has been confirmed in the safety of avastin in lung
ancer (SAiL) study, an international open-label, multicenter, single-
rm phase IV trial.23 The SAiL trial extended the clinical experience
f bevacizumab by allowing the use of chemotherapy regimens other
han those investigated in the pivotal trials, and by including patients
ith an ECOG performance status (PS) of 2. In this study, 2212
atients received bevacizumab (7.5 or 15 mg/kg, I.V., every 21 days)
lus standard chemotherapy for up to six cycles, followed by single-
gent bevacizumab until progression; of this population, 86% had
denocarcinoma. Grade3 adverse events (AEs) were relatively un-
ommon: bleeding in 3.6% of patients, pulmonary hemorrhage in
.7%, hypertension in 5.7%, proteinuria in 3.0%, and thromboem-
olism in 7.8%.23 Additionally, the efficacy data were consistent
with results observed in the two pivotal phase III trials: median OS of
14.6 months, median time to progression (TTP) of 7.8 months, and
overall response rate of 51.6%.
The Avastin Registry: Investigation of Effectiveness and Safety
(ARIES) registry, an observational cohort trial, has enrolled 1970
patients with advanced NSCLC. Preliminary safety results were re-
cently presented and confirmed the safety profile of bevacizumab-
based therapy with AE rates consistent with previous reports.24
The mechanisms of resistance to cytotoxic drugs are typically
the result of genetic instability inherent in cancer that renders
mutant cells insensitive to chemotherapeutic agents. The mecha-
nisms of resistance for biologic agents, such as bevacizumab, are not
well understood. Failure of chemotherapy does not necessarily mean
failure of antiangiogenic treatment with bevacizumab, implying that
the disease may still be partially or significantly dependent on VEGF-
mediated endothelial cell mitogenesis and survival. The angiogenic
signal continues throughout the lifespan of the tumor. One hypoth-
esis is that persistent VEGF suppression, along with secondary and
tertiary cytotoxic regimens, may result in continued clinical benefit.
This hypothesis is supported by the experience of patients with met-
astatic colorectal cancer (mCRC) enrolled in the Bevacizumab Reg-
hCesare Gridelli et alimens’ Investigation of Treatment Effects (BRiTE) tumor registry, a
large, prospective, observational trial of patients with mCRC who
had received chemotherapy and bevacizumab. Data from BRiTE
demonstrated that patients whose disease had progressed on first-line
treatment with bevacizumab, but who continued to receive bevaci-
zumab plus chemotherapy beyond first progressive disease (PD), had
a statistically significant improvement in survival beyond first PD
compared to patients who received chemotherapy alone in subse-
quent lines. Patients who received no treatment beyond first PD
(n 253) had a median OS of 12.6 months, patients who received
chemotherapy but no bevacizumab beyond first PD (n 531), had
a median OS of 19.9 months, and patients receiving bevacizumab
(n 642), usually in conjunction with other agents, beyond first PD
ad a median OS of 31.8 months (HR  0.48; 95% confidence
interval [CI], 0.41-0.57; P  0.001).25
Based on these considerations, the current, randomized trial was de-
signed to evaluate whether bevacizumab in combination with standard
treatment for NSCLC versus standard of care alone in second-line and
subsequent lines of treatment could improve OS in patients who have
progressed after first-line treatment with bevacizumab plus a platinum-
based doublet (ClinicalTrials.gov Identifier: NCT01351415).
Objectives
The primary endpoint of this study was to assess the efficacy of
continued bevacizumab treatment beyond PD after first-line treat-
ment as measured by OS, defined as the time from the date of ran-
domization at first PD to the date of death, regardless of the cause of
death. Secondary endpoints include the assessment of efficacy as
measured by the rate of 6-month, 12-month, and 18-month survival
measured from randomization at first PD; by PFS and TTP from
randomization at first PD to second and third PD; and by response
rates, disease control rates, and duration of response at second and
third PD. Additional secondary objectives include comparison of the
efficacy between patients with adenocarcinoma and nonadenocarci-
noma, and the safety of bevacizumab treatment across multiple lines
of treatment. Exploratory objectives include assessment of the qual-
ity of life (QoL) through multiple lines of treatment, and the com-
parison of the efficacy between Asian and non-Asian patients. Bio-
marker samples will be used to explore the correlation of biomarkers
with efficacy outcomes, to investigate early, intermediate, and late
escape mechanisms related to bevacizumab in combination with
standard treatment regimens, to explore the association of biomark-
ers with response and AEs, and to develop biomarker assays and to
establish the performance characteristics of these assays.
Eligibility Criteria
Study entry is limited to patients aged 18 years of age with
histologically or cytologically confirmed non-squamous locally re-
current or metastatic NSCLC with documented PD after first-line
treatment with four to six cycles of bevacizumab plus a platinum-
based doublet and a minimum of two cycles of bevacizumab (mono-
therapy) maintenance treatment before PD, with ECOG PS 0 to 2.
Adequate bone marrow, renal, and liver function are required. Pa-
tients with asymptomatic, treated brain metastases are eligible for
trial participation.
Exclusions include mixed adenosquamous carcinomas with a pre-
dominant squamous component, EGFR–mutation-positive diseaseaccording to local laboratory testing (if performed per institutional
standard), evidence of tumor invading a major blood vessel, history
of hemoptysis of grade 2, inherited bleeding diathesis, or coagu-
lopathy with a risk of bleeding, active gastrointestinal bleeding, clin-
ically significant cardiovascular disease, uncontrolled hypertension,
or patients with malignancy other than NSCLC within 5 years before
randomization (with the exception of nonmelanomatous skin cancer
or adequately treated carcinoma in situ of the cervix). Institutional
review board-approved informed consent will be obtained for every
patient before initiation of any trial-specific procedure or treatment.
Treatment Plan
This is an international, multicenter, open-label, randomized,
two-arm, phase IIIB trial. Patients who develop PD after four to six
cycles of first-line treatment with bevacizumab plus a platinum dou-
blet-containing chemotherapy regimen and a minimum of two cy-
cles of bevacizumab (monotherapy) maintenance treatment will be
randomized at documentation of PD in a 1:1 ratio to one of two
study arms (Figure 1). Patients treated on arm A will receive bevaci-
zumab (7.5 or 15 mg/kg, I.V., on day 1, every 21 days) combined
with investigator’s choice of agents indicated for use in second-line
(limited to docetaxel, pemetrexed, or erlotinib) and subsequent lines
of treatment. Beyond second PD, bevacizumab may be continued
through subsequent lines of treatment at the investigator’s discretion
in the absence of unacceptable toxicity or consent withdrawal. Pa-
tients treated on arm B will receive investigator’s choice of agents
indicated for use in second-line and subsequent lines of treatment.
No crossover is permitted. All agents must be given on day 1 every 21
days. Dose of bevacizumab (7.5 or 15 mg/kg, I.V., every 21 days) will
be identical to that administered during first-line treatment and
maintenance, and the same dose must be continued during all lines
of treatment.
Before starting any study treatment, computed tomography scans
of the brain, chest, and abdomen, 12-lead electrocardiogram, and a
bone scan are required. Further assessments will be performed as
clinically indicated. Tumor response, based on investigator-assessed
Response Evaluation Criteria in Solid Tumors (RECIST v.1.1), will
be evaluated every two cycles during second-line treatment, and ev-
ery three cycles during third-line treatment. QoL will be assessed
using the core module, European Organization for Research and
Treatment of Cancer (EORTC) Quality of Life Questionnaire
(QLQ)-C30, and lung cancer-specific module, QLQ-LC13, which
will be completed by patients at baseline and before each cycle during
treatment.26 All patients who prematurely discontinue treatment for
any reason will be followed for survival.
Expected Results and Toxicities
The sample size calculation for this trial is based on a 24-month
recruitment period and minimum follow-up of 12 months. There
will be one interim analysis for efficacy. Assuming a median OS
beyond PD of 7.9 months (1-year OS rate 35%) in the control
group, 10.1 months (1-year OS rate 44%) in the treatment arm
(corresponding to HR of 0.78), and one efficacy interim analysis,
then 528 events are required to achieve 80% power for the log-rank
test at a two-sided significance level of 5%. To observe the required
events in the timeframe specified above, approximately 293 patients
per treatment arm are necessary (approximately 586 patients in to-
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410tal). The efficacy interim analysis will be performed after 70% of OS
events (370 events) are observed. The interim analysis will follow a
sequential plan according to O’Brien-Fleming boundary27 as imple-
ented by Lan and DeMets.27 The significance levels for the interim
and final efficacy analyses will be 0.0148 and 0.0455, respectively.
The overall study wide significance level for this procedure will be
0.05. The interim efficacy analysis will be performed by an Indepen-
dent Data Monitoring Committee. To allow for a dropout rate of
about 2% post-randomization, the final sample size will be approx-
imately 600 patients (300 per treatment arm). Eligible patients will
be randomized via an IW/VRS system, through a central stratified
block randomization process using the following stratification fac-
tors: type of planned second-line standard treatment (erlotinib vs.
docetaxel vs. pemetrexed); number of cycles of bevacizumab main-
tenance treatment (6 vs.6); smoking status (never vs. former vs.
current).
Analytical Methods
The primary and secondary efficacy endpoint analyses will be per-
formed on the intent-to-treat (ITT) population, defined as all con-
senting patients randomized to trial treatment. Patients in the ITT
population will be assigned to a treatment group based on the treat-
ment to which they are randomized. For the duration of OS, patients
with an unknown survival status will be censored when they were last
known to be alive. The duration of PFS for patients who have not
died (or are not known to have died, or are lost to follow-up) at the
time of analysis will be censored as of the date the patient was last
known to be progression-free or at the last follow-up for PD. Patients
for whom no post-baseline tumor assessments are available will be
censored at the day of randomization. Differences in OS and PFS
between treatment arms will be tested with a stratified log-rank test
Figure 1 AvaALL (MO22097) Treatment Design. Arm A: Patient
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Clinical Lung Cancer November 2011plan-Meier curves will be displayed, with median PFS estimates and
95% CIs provided for each treatment arm. The OS estimates and
corresponding 95% CIs at 6 months, 12 months, and 18 months will
also be presented. The difference in OS between the treatment arms
will be tested with a stratified log-rank test. Response rates and dis-
ease control rates will be summarized by treatment arm and the
estimated difference in response rates and the associated 95% CIs
will be provided. The Cochran-Mantel Haenszel test, stratified by
the same factors used at randomization will be used to compare the
overall response rate between the treatment arms. An unadjusted 2
test result will also be provided. Differences in duration of response
will be tested for descriptive purposes with a stratified log-rank test.
Kaplan-Meier curves will be displayed with median duration esti-
mates and confidence limits provided. The efficacy analyses de-
scribed above will be also shown for the subgroups of patients with
adenocarcinoma and nonadenocarcinoma.
Safety results will be based on the safety population, defined as all
patients who received at least one dose of trial drug after randomiza-
tion, and patients will be assigned to treatment groups based on what
they actually received. All AEs and abnormal laboratory variables will
be reported and graded according to National Cancer Institute Com-
mon Terminology Criteria, version 4.0. The QoL scales and the
proportion of patients with improvement, decline, or no change in
their health-related QoL will be summarized by descriptive summary
tables at baseline and over time.
Summary
The AvaALL (MO22097) trial is designed to examine the clinical
benefit and safety of continued bevacizumab treatment beyond first
PD in patients with advanced non-squamous NSCLC whose disease
progresses after four to six cycles of first-line treatment with bevaci-
l Receive Bevacizumab 7.5 mg/kg or 15 mg/kg I.V., on Day 1,
tment From Cycle 1 Until the Occurrence of Unacceptable
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tment. Arm B: Patients Will Receive Standard of Care
ty or Withdrawal of Consent (whichever occurs first).
r Progressive Disease
PD2
Primary endpoint: OS
PD3
SOC2a
+
evacizumab
SOC3b
+
bevacizumab
SOC4
±
bevacizumab
SOC2a
 (erlotinib, pemetrexed and docetaxel)
ator’s choice
SOC3b SOC4s Wil
Trea
first
Trea
oxici
city o
b
SCLC
vestigzumab plus a platinum-based doublet and a minimum of two cycles
11
1
Cesare Gridelli et alof bevacizumab (monotherapy) maintenance treatment. Patients will
be randomized to receive either bevacizumab plus standard of care
treatment or standard of care treatment alone after first PD. Patients
will be monitored and assessed throughout the duration of the study
as described above. The primary endpoint of this study is OS, and a
number of secondary and exploratory objectives will also be
obtained.
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